Business Wire

NY-SONIC-ENTERPRISES

2.5.2022 14:08:04 CEST | Business Wire | Press release

Share
World-Renowned and Globally Recognized Photographer Anne Geddes Brings Her Artistry and Creativity to NFTs for the First Time With Her Mother’s Day 2022 Collection

Anne Geddes , photographer globally renowned for her iconic imagery capturing the beauty, purity, and joy of new life, brings her artistry and creativity to NFTs for the first time. On May 6, 2022, the Anne Geddes Mother’s Day 2022 NFT Collection will drop at 9 a.m. PT, commemorating the holiday. The Collection contains nine selections made available in a variety of format configurations. Her highly anticipated collection will be sold exclusively through the certified carbon-neutral blockchain marketplace WAX and powered by the Shopify app Waxify . Her renowned artwork will be available for purchase in FIAT (USD) through credit card, PayPal and other traditional payments as well as WAXP, Bitcoin, and Ethereum. This crossover collection seamlessly bridges the gap between the mainstream Anne Geddes photography collectors and avid NFT collectors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220502005269/en/

Buyers can pre-register for the sale at annegeddes.io , with a pre-sale beginning a day prior — May 5, 2022, at 9 a.m. PT.

The configurations of the collection include:

Limited Edition Digital Prints:

All nine images in the Mother's Day collection are minted as digital art prints. Every digital print can be "redeemed" for a corresponding physical 8”x10” print.

Signature Series:

All nine images from the collection make up the “Signature Series.” Every digital print will feature an original authenticated digital signature and a signed physical print. Only 20 of each print will be available for a total of 180 prints. These prints are created exclusively for the Anne Geddes Mother’s Day 2022 NFT Collection.

1-of-1 Collection:

Two images from the collection will be available as limited edition one-of-one digital and physical prints. Each image will feature an authenticated original digital signature and a signed one-of-a-kind physical print.

Each artfully minted NFT will come with an exclusive redemption offering for a physical piece of art, made exclusively for this release. Every NFT will also contain a minted video of Anne personally discussing each of the images. Additionally, all digital and physical prints will be made exclusively for this release and will not be made again in this format.

Anne will also be auctioning off one elusive private shoot in her studio in New York to raise money for mothers and children in Ukraine. An additional commemorative NFT to support Ukrainian children will be available in the gallery to help raise additional funds. All proceeds will be provided to The American Red Cross.

While Anne’s photography has been treasured and respected by many generations, her evocative move into the blockchain with an iconic Anne Geddes Mother's Day NFT Collection is groundbreaking for an artist of this caliber.

Link:

ClickThru

Social Media:

https://www.facebook.com/annegeddes

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye